Anti-Cancer Agents in Medicinal Chemistry is a pivotal journal in the realm of cancer research, published by Bentham Science Publishers in the United Arab Emirates. With an ISSN of 1871-5206 and an E-ISSN of 1875-5992, this esteemed journal has been disseminating high-quality research since its inception in 2006, and is set to continue through 2024. The journal is categorized in the third quartile (Q3) across key areas including Cancer Research, Molecular Medicine, and Pharmacology, highlighting its essential role in providing valuable insights to the scientific community. Despite its open-access status being unspecified, researchers benefit from the rigorous peer-review process ensuring the publication of significant advancements. The journal ranks well within Scopus, particularly in the fields of Pharmacology and Cancer Research, which positions it as a notable resource for professionals, students, and researchers aiming to deepen their knowledge in anti-cancer strategies. Through its comprehensive scope, the journal aims to bridge the gap between medicinal chemistry and clinical applications, making it an indispensable tool for those dedicated to advancing cancer therapeutics.

MOLECULAR DIVERSITY, published by Springer, stands as a pivotal platform within the fields of chemistry, biology, and pharmacology since its inception in 1995. This esteemed journal aims to foster interdisciplinary research and innovation, particularly in areas such as catalysis, drug discovery, inorganic and organic chemistry, and molecular biology. With a diverse scope that reflects contemporary scientific challenges, it has been recognized for its significant contributions, boasting commendable Scopus rankings and an impact factor that underscores its relevance in critical fields. Although not an open access journal, MOLECULAR DIVERSITY continues to influence and engage researchers, professionals, and students alike by providing a forum for high-quality peer-reviewed articles and cutting-edge research findings. As it converges years of scientific dynamism from 1995 to 2024, this journal remains vital for those advancing the frontiers of molecular science and engineering.

HETEROCYCLES, published by the Japan Institute of Heterocyclic Chemistry, stands as a pivotal journal within the fields of Analytical Chemistry, Organic Chemistry, and Pharmacology. With its ISSN 0385-5414 and E-ISSN 1881-0942, HETEROCYCLES has been a respected platform for scholarly work since its establishment in 1983, featuring innovative research up until 2022. While currently not open access, the journal is renowned for its rigorous peer-review process, ensuring the dissemination of high-quality research. Despite its Q4 ranking in the 2023 quartiles for its categories, it plays a crucial role in bridging gaps in knowledge and advancing the discourse on heterocyclic compounds, which are vital in drug discovery and development. Researchers, professionals, and students who are engaged in chemistry and pharmacology will find HETEROCYCLES an essential source of cutting-edge studies, insights, and an opportunity to contribute to the evolving landscape of these scientific fields.

Heteroatom Chemistry is a prominent open-access journal dedicated to advancing the field of heteroatom chemistry, with a particular focus on the chemistry of elements other than carbon in organic compounds. Published by Wiley-Hindawi, this journal provides researchers, professionals, and students with a platform to disseminate and access novel research findings related to the synthesis, properties, and applications of heteroatom-containing compounds. Since its inception in 1990 and gaining open access status in 2019, the journal has fostered academic collaboration and innovation throughout its converged years, although it currently holds a category quartile ranking of Q4 in Chemistry (miscellaneous) and ranks #319 out of 408 in general chemistry within Scopus. With its commitment to high-quality research and broad accessibility, Heteroatom Chemistry is poised to be an essential resource for anyone looking to explore the rich and varied applications of heteroatom chemistry in diverse scientific fields.

ChemMedChem is a leading international journal published by WILEY-V C H VERLAG GMBH in the United Kingdom, specializing in the interdisciplinary fields of medicinal chemistry and drug discovery. With a commendable impact factor that places it in the Q1 quartile for Organic Chemistry and among the Q2 ranks in several other key categories including Biochemistry, Molecular Medicine, and Pharmacology, ChemMedChem serves as a vital platform for the dissemination of innovative research and transformative insights in the development of pharmaceutical agents. Since its inception in 2006, this journal has been at the forefront of advancing knowledge that bridges the gap between fundamental research and practical applications in medicine, making it an essential resource for researchers, professionals, and students alike. Although it currently does not offer Open Access options, the journal ensures high-quality peer-reviewed content that engages its audience and fosters collaborative scientific discourse.

Chemical Biology & Drug Design, an esteemed publication by WILEY, serves as a vital platform for the dissemination of pioneering research in the interdisciplinary fields of biochemistry, drug discovery, molecular medicine, organic chemistry, and pharmacology. With a dedicated commitment to advancing the understanding of chemical interactions and drug development, this journal not only fosters innovation but also bridges the gap between theoretical research and practical applications. It boasts an impressive impact factor and is recognized in the 2023 category quartiles as Q3 in Biochemistry and Molecular Medicine, and Q2 in Drug Discovery, Organic Chemistry, and Pharmacology, indicating its relevance and influence in these crucial areas. The journal’s rankings across various Scopus categories further solidify its position as a reputable resource for researchers, professionals, and students striving to stay at the forefront of medicinal chemistry and drug design. While primarily traditional access-based, the journal's evolving scope from 2006 to 2024 ensures an ongoing contribution to essential scientific dialogue, making it an indispensable read for those committed to advancing health sciences.

Chemistry Letters, published by the Chemical Society of Japan, is a distinguished academic journal that focuses on pivotal developments in the field of chemistry. Since its inception in 1973, the journal has been a vital platform for the dissemination of novel research findings across various sub-disciplines, encompassing both theoretical advancements and practical applications. As a testament to its significance in the community, Chemistry Letters has achieved a Category Quartile of Q2 in the 2023 ranking for miscellaneous Chemistry journals, reflecting its respected position among peers. Although it does not offer Open Access, the journal remains accessible through institutional subscriptions, thus ensuring a wide reach for its valuable content. With an active scope ranging from general chemistry topics to specialized studies, it is ideal for researchers, professionals, and students alike who seek to contribute to and expand their knowledge within this dynamic field. The journal continuously aims to promote excellence in chemical research, facilitating dialogue and collaboration among chemists worldwide.

Current Medicinal Chemistry is a leading journal published by Bentham Science Publishers Ltd, known for its rigorous focus on the multifaceted realm of medicinal chemistry. With an ISSN of 0929-8673 and E-ISSN 1875-533X, the journal plays a crucial role in disseminating high-quality research findings that bridge the gap between chemistry and health sciences. Operating from Sharjah, United Arab Emirates, it has been a prominent scholarly resource since its inception in 1994, and is expected to continue until 2024. Current Medicinal Chemistry has earned its place in the academic community with an impressive impact factor and categorization in Q1 and Q2 quartiles across various disciplines, including Organic Chemistry, Biochemistry, Drug Discovery, and Pharmacology, highlighting its substantial contribution to these fields. Notably, it ranks 24th in Organic Chemistry and is within the 88th percentile, underscoring its appeal to researchers, professionals, and students alike who are keen on exploring cutting-edge advancements in drug design and development. Although it is not an open-access journal, it provides vital content that informs and inspires innovation in medicinal chemistry, appealing to a global audience committed to enhancing human health through scientific discovery.

European Journal of Medicinal Chemistry, a premier publication by Elsevier France-Editions Scientifiques Médicales Elsevier, has been at the forefront of advancing medicinal chemistry since its inception in 1974. With an impressive impact factor and ranking in the Q1 quartile across multiple categories including Drug Discovery, Medicine (miscellaneous), Organic Chemistry, and Pharmacology, this journal delivers cutting-edge research and reviews that are vital for researchers and professionals in the field. The journal’s scope encompasses the design, synthesis, and evaluation of biological activity of bioactive compounds, making it a critical resource for those looking to innovate in drug development and therapeutic strategies. Although currently not open access, subscribers can benefit from its diverse range of high-quality articles, ensuring the dissemination of knowledge in the ever-evolving landscape of medicinal chemistry. The European Journal of Medicinal Chemistry continues to play a pivotal role in shaping the future of pharmacological research and its application, thus appealing to an audience dedicated to making impactful scientific contributions.

MINI-REVIEWS IN MEDICINAL CHEMISTRY is a distinguished journal published by Bentham Science Publishers, dedicated to the cutting-edge field of medicinal chemistry. With an ISSN of 1389-5575 and an E-ISSN of 1875-5607, this journal serves as an essential platform for researchers and professionals to disseminate concise yet comprehensive reviews that capture the latest advancements and trends in drug discovery, cancer research, pharmacology, and molecular medicine. Operating since 2001, it has consistently maintained a relevant presence in academia with its impressive rank metrics, including a Q2 category in Drug Discovery and Pharmacology in 2023, highlighting its significance in the scientific community. The journal is recognized for its rigorous peer-review process and provides an invaluable resource for students and researchers seeking insights into the rapidly evolving landscape of medicinal chemistry. With a commitment to excellence and innovation, MINI-REVIEWS IN MEDICINAL CHEMISTRY continues to foster knowledge exchange and inspire future breakthroughs in healthcare and therapeutic advancements.